key: cord-0728212-6umcutr3 authors: Mercado-Reyes, Marcela; Malagón-Rojas, Jeadran; Rodríguez-Barraquer, Isabel; Zapata-Bedoya, Silvana; Wiesner, Magdalena; Cucunubá, Zulma; Toloza-Pérez, Yesith Guillermo; Hernández-Ortiz, Juan P.; Acosta-Reyes, Jorge; Parra-Barrera, Eliana; Ibáñez-Beltrán, Edgar; Quinche, Gianni G; Muñoz-Galindo, Lyda; Rubio, Vivian; Galindo-Borda, Marisol; Osorio-Velázquez, Erickson G; Bermúdez-Forero, Andrea; Pinto-Chacón, Nelson; Puerto-Castro, Gloria; Franco-Muñoz, Carlos; Estupiñan, María Isabel; Villar, Luis Ángel; Gore-Saravia, Nancy; Miranda-Montoya, María Consuelo; Castellanos, Jaime; Valle, Edna Margarita; Navarro-Lechuga, Edgar; Oviedo, Juan Daniel; Ospina-Martínez, Martha title: Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study date: 2022-02-05 journal: Lancet Reg Health Am DOI: 10.1016/j.lana.2022.100195 sha: 675e9d0c3db4d9dd4d432b2b34e6e85aad8c6910 doc_id: 728212 cord_uid: 6umcutr3 BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause very high morbidity and mortality throughout Latin American countries. However, few population-based seroprevalence surveys have been conducted to quantify attack rates and characterize drivers of transmission. METHODS: We conducted a population-based cross-sectional study to assess the seroprevalence of antibodies against SARS-CoV-2 in ten cities in Colombia between September and December 2020. The study involved multi-stage cluster sampling at each city. Participants provided a serum sample and answered a demographic and risk factor questionnaire. Prior infection by SARS-CoV-2 was ascertained using the "SARS-CoV-2 Total (COV2T) Advia Centaur - Siemens" chemiluminescence assay. FINDINGS: A total of 17863 participants from 7320 households participated in the study. Seroprevalence varied substantially between cities, ranging from 26% (95%CI 23–29 %) in Medellín to 68% (95%CI 62–74 %) in Guapi. There were no differences in seroprevalence by sex, but seropositivity was higher in certain ethnic groups. There was substantial heterogeneity in seroprevalence within cities, driven to a large extent by a strong association between socioeconomic stratum and seropositivity. INTERPRETATION: Colombia has been one of the Latin American countries most affected by the COVID-19 pandemic. This study documented very high attack rates in several Colombian cities by the end of 2020 and identified key drivers of heterogeneities including ethnicity and socioeconomic stratum. Few studies of seroprevalence of SARS-CoV-2 have been conducted in Latin America, and therefore this study contributes to the fundamental understanding of the pandemic in the region. FUNDING: The study was sponsored by, Ministerio de Ciencia y Tecnología e Innovación –CT361/2020, Ministerio de Salud y Protección Social, Fundación Universitaria del Norte, Imperial College of London, Universidad Nacional de Colombia (Sede Medellín), Universidad de Córdoba, California University, Unidad Nacional de Gestión del Riesgo, Centro de Atención y Diagnóstico de Enfermedades Infecciosas -CDI-, Centro Internacional de Entrenamiento e Investigaciones Médicas -CIDEIM-, Departamento Administrativo Nacional de Estadística - DANE, Fondo Nacional de Turismo -FONTUR-, Secretarías de Salud Departamentales, Distritales y Municipales and Instituto Nacional de Salud. Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause very high morbidity and mortality throughout Latin American countries. However, few population-based seroprevalence surveys have been conducted to quantify attack rates and characterize drivers of transmission. Methods We conducted a population-based cross-sectional study to assess the seroprevalence of antibodies against SARS-CoV-2 in ten cities in Colombia between September and December 2020. The study involved multi-stage cluster sampling at each city. Participants provided a serum sample and answered a demographic and risk factor questionnaire. Prior infection by SARS-CoV-2 was ascertained using the "SARS-CoV-2 Total (COV2T) Advia Centaur -Siemens" chemiluminescence assay. Findings A total of 17863 participants from 7320 households participated in the study. Seroprevalence varied substantially between cities, ranging from 26% (95%CI 23−29 %) in Medell ın to 68% (95%CI 62−74 %) in Guapi. There were no differences in seroprevalence by sex, but seropositivity was higher in certain ethnic groups. There was substantial heterogeneity in seroprevalence within cities, driven to a large extent by a strong association between socioeconomic stratum and seropositivity. Interpretation Colombia has been one of the Latin American countries most affected by the COVID-19 pandemic. This study documented very high attack rates in several Colombian cities by the end of 2020 and identified key drivers of heterogeneities including ethnicity and socioeconomic stratum. Few studies of seroprevalence of SARS-CoV-2 have been conducted in Latin America, and therefore this study contributes to the fundamental understanding of the pandemic in the region. Colombia is one of the most affected countries by COVID-19 in Latin America. Surveillance data suggests that the epidemic has been heterogeneous throughout the country, with early peaks in the North Coast and Amazonian border and later peaks elsewhere. Nevertheless, in the absence of seroprevalence studies, the true infection rate in Colombia remains unknown. We searched PubMed, Embase, and the Serotracker Ò Database for publications on the seroprevalence of SARS-CoV-2 antibodies, using the search terms "SARS-CoV-2", "COVID-19", "seroprevalence", "Latin America" from September to December, 2020. Except for Brazil and some studies in Iquitos (Per u), Montería y Bucaramanga (Colombia) there is a lack of seroprevalence studies from Latin America region. Furthermore, in most studies, the overall prevalence estimates were not further stratified by geographical areas and did not bear in mind the changes of infection rate across various regions. In this population-based study we assessed the seroprevalence of SARS-CoV-2-specific antibodies in some of the most populated cities in Colombia. This is the first seroprevalence study in the Andean region to report the prevalence of anti-SARS-CoV-2 antibodies in the general population during the second semester of 2020. Our findings imply that almost 4¢1 million of individuals from the included cities were infected between March and December 2020. Seroprevalence estimates of SARS-CoV-2-specific antibodies presented an elevated heterogeneity across the general populations in different cities, ranging from 26% to 68%. Compared with other seroprevalence studies from America, Asia and Europe, the seroprevalence estimates in the general population of Colombia in this study were high. In spite of schools having been closed since March 2020, we observed that children and adolescents showed seroprevalence levels similar to the observed in young adults. In contrast, we observed consistently lower seroprevalence levels in adults older than 65 years in cities with late epidemics, with respect to those with early epidemics. Population-based serological surveys are the gold standard to estimate what proportion of a population has been exposed to a pathogen. For SARS-CoV-2, and due to a large number of asymptomatic and mildly symptomatic cases, surveillance systems that rely on symptomatic cases are insufficient to estimate the total number of infections at the community level. 1 The World Health Organization (WHO) has underscored the relevance of studies quantifying the extent of SARS-CoV-2 transmission at the country level. 2 More importantly, quantifying SARS-CoV-2 seroprevalence is crucial to better understand the transmission dynamics, guiding novel avenues to design and implement public health interventions. 3 Nevertheless, except for cities in Brazil, few studies have been conducted in Latin American cities, despite the very high disease burden. Between March and December 2020 there were more than 1¢5 million confirmed cases and more than 43 thousand COVID-19 related deaths in Colombia. 4 A national lockdown was in place between March 25th and April 15th, followed by a slow but steady increase in mobility until August 2020. Since September, COVID-19 mitigation strategies and implementation of nonpharmaceutical interventions (NPIs) have been largely enforced at a local level, often guided by intensive care unit (ICU) occupancy rates. Similar to what has been observed in other settings, the SARS-CoV-2 epidemic in Colombia has been highly spatially heterogeneous. While some municipalities experienced explosive early peaks followed by periods of very low transmission despite the near absence of NPIs, many others have experienced several moderate peaks interspersed with plateaus of sustained transmission. In this study, we aimed to provide a comprehensive panorama of the pandemic in Colombia by measuring the seroprevalence of antibodies against SARS-CoV-2 in ten selected cities during the second semester of 2020. We designed a population-based cross-sectional study to measure the seroprevalence of antibodies against SARS-CoV-2 in ten cities across Colombia. The selected cities included seven of the ten most populated cities in Colombia (Bogot a, Medell ın, Cali, Barranquilla, Cucuta, Bucaramanga and Villavicencio) as well as cities in key border regions (Leticia, Ipiales and Guapi). We conducted multi-stage cluster sampling using updated population projections and maps from the national statistical office (DANE). The source population included all the non-institutionalized civilian population Articles between the ages of five and 80 years old, residing in the urban areas of each city (suburbs were not included). In the first stage, blocks -the primary sampling unit (PSU)were selected with probability proportional to their population size. In the second stage, segments were selected by randomly sampling clusters of five contiguous dwellings. Households within each segment were invited to participate and surveyed. The sample size was estimated assuming a seroprevalence of 30%, 5 and marginal sampling errors of 3% for Bogota, Cali, and Medellin, 3¢5% for Leticia, Barranquilla, Bucaramanga, C ucuta, Villavicencio and Ipiales, and 5¢0% for Guapi and regions with geographically restricted access. These were equivalent to relative errors of 5%, 6% and 8¢5%, respectively. Based on results from prior household surveys conducted by DANE, we assumed a design effect of 2. Detailed information on sample size calculation is provided in Supplementary Table 1 . The fieldwork took place between September 21st and December 11th, 2020. Specific dates for each city are listed in Supplementary Table 1 . The locations were visited in random order by the study teams, and selected households were approached and invited to participate. Due to logistical constraints, non-responding households were visited three times before neighboring households were invited to participate. Individuals in the selected households were invited to participate and asked to sign a consent form. All participants were asked to provide a venous blood sample (6 to 7 mL) and to respond to the study questionnaire. In addition, a nasopharyngeal swab was obtained from participants who reported having any symptoms associated with COVID-19 at the time of the visit. After collection, blood samples were refrigerated and transported to a local laboratory where they were centrifuged to separate the serum. They were then stored at -30°C to -80°C until processing. The study questionnaire included 52 questions on sociodemographic characteristics, potential risk factors for COVID-19 transmission, household characteristics, and behavior related to a COVID-19 infection. Before the initiation of the survey, this questionnaire was developed and validated by five experts who assessed clarity, coherence, relevance, and sufficiency. The questionnaire was piloted among 100 volunteers from Bogot a. RedCap Ò V. 10.1.2 (free license) was used to record the geographic and survey information. Prior infection by SARS-CoV2 was ascertained by measuring total antibodies (IgM+ IgG) using the SARS-CoV-2 Total (COV2T) Advia Centaur − Siemens chemiluminescent immunoassay (CLIA). 6 The COV2T is an in-sandwich one-step automated antigen test for the qualitative detection of total antibodies (IgM + IgG), against the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 virus, in serum or plasma. This CLIA assay was selected based on the good performance reported by prior published studies and after performing an internal validation with samples from the Colombian population. Negative controls included 221 serum samples collected before 2010, including samples from impatiens with Dengue, Zika and other arboviruses. Sera from 149 patients with SARS-CoV-2 infection, confirmed by RT-PCR and obtained less than 14 days after the onset of symptoms, were used as positive controls. This validation resulted in a sensitivity of 86% (95% CI% 79−91%) and specificity of 99% (95% CI 96 −100%). 6 Nasopharyngeal swab samples were refrigerated and transported to the local laboratory in each city. The RNA was extracted and amplified according to the Berlin protocol, which was validated by the Colombian National Institute of Health (Instituto Nacional de Salud, INS). 7 Viral RNA extraction was performed by using the QIAamp Viral RNA Mini kit (Qiagen Inc., Chatsworth, CA, USA) or the MagNA Pure LC nucleic acid extraction system (Roche Diagnostics GmbH, Mannheim, Germany). 8 All positive samples by RT-PCR were sequenced. The library preparation and sequencing were performed following the ARTIC network (realtime molecular epidemiology for outbreak response) protocol and using Oxford Nanopore Technologies (Oxford Nanopore Technologies, Oxford. 8 The SARS-CoV-2 genome sequences were deposited in GISAID. The sequences were compiled and combined with representative genome sequences from the South Americafocused subsampling available from NextStrain. General descriptive statistics were used to explore and compare the characteristics of participants and households. For each city we report crude seropositivity estimates as well as adjusted estimates that are jointly (a) weighted to match the population structure of each city by age, sex and socio-economic stratum, (b) adjusted for test-performance characteristics and (c) took into account clustering at the block level. Weights (expansion factors) were calculated using previously established methodology 9 by the National Statistical Office (DANE), and also considered aspects of survey design and non-response as described in Supplementary Table 2 . Corrections for test performance used the method proposed by Gelman and Carpenter 10 and data on the sensitivity and specificity of the assay measured by internal validation. Details on the model used for this adjustment are provided in the Supplementary Methods file. To characterize associations between sociodemographic factors and seropositivity, we fit mixed-effect Poisson models using the lmer package in R, to estimate prevalence ratios and 95% confidence intervals. 11, 12 All models included a random effect for blocks to account for clustering at this level. The Akaike information criterion (AIC) was used to compare the fit of competing models. To ensure that all models included the same number of observations, multivariate models were fit using a complete dataset where observations that contained missing data in any of the included variables were deleted. Results from an alternative analysis where missing observations were coded as a "missing" category can be found in Supplementary The study proposal and protocol were approved by the ethics committee of Instituto Nacional de Salud (CEMIN 010/2020). We obtained written informed consent from each adult participant as well as oral assent and written parental permission from all participants between five and 17 years of age. Beside the funding, the Ministerio de Ciencia y Tecnolog ıa e Innovaci on had no role in the study design, data collection, data analysis, data interpretation, or writing the report. The study included samples from 7,320 households, accounting for 17,863 participants from the ten selected Colombian cities, i.e. Bogot a (n = 4,515; 25¢2%), Barranquilla (n = 1,431; 8¢0%), Bucaramanga (n = 1,427; 7¢9%), Cali (n = 1,983; 11¢1%), C ucuta (n = 1,448; 8¢1%), Medell ın (n = 1,987; 11¢1%), Villavicencio (n = 1,467; 8¢2%), Leticia (n = 1,417; 7¢9%), Ipiales (n = 1,465; 8¢2%), and Guapi (n = 712; 4¢0%) (Supplementary Table 1 ). Household response rates ranged between 82% and 90%. Among eligible individuals from participating households, the median response rate was 90% but ranged between 83% and 95% (Supplementary Table 2 ). Characteristics of participating households, and participants are described in Table 1 . The median size of participating households was two persons (range: 1−17 persons). The majority of households (4122/7320, 56¢3 %) belonged to the lowest socio-economic strata (strata 1 and 2). This is a 6-level classification system used in Colombia that serves as an indicator of a household's socio-economic conditions. The average age of participants was 37¢1 § 20¢7 years old and females accounted for 61¢47% of the sample (n = 10,980), due to a lower response rate in males ( Table 1) . Almost 99% (n = 15,421/15,647 participants who answered this question) of participants asserted to wash their hands with soap regularly (once or more per day). 98% (n = 14,803/ 15,132) declared that they used a face mask whenever they left home. Only 764 (4.3%) participants reported having been diagnosed with COVID-19 in the prior months, but 2843 (15.91%) reported "having been in contact with a COVID-19 case". Characteristics of the participants enrolled in each city are reported in Supplementary Tables 3−12. A total of 5811/17,863 (32¢25%) participants tested positive for antibodies against SARS-CoV-2. As expected, crude seroprevalence was heterogeneous between cities and ranged between 26% and 59% ( Table 2 ). After correcting for the sensitivity and specificity of the test and weighting for age, sex and socioeconomic stratum, our results suggest that more than 50% of the population had been infected in Barranquilla, Guapi and Leticia by the time of the survey (September to December 2020) ( Table 2, Supplementary Table 13 ). Except for Bucaramanga and C ucuta, higher seroprevalence levels were observed in cities with populations of 1¢5 million or less ( Table 2 ). Cities that experienced the first peak during the first semester of 2020 showed higher seroprevalence levels (Fig. 1) . Seroprevalence was highest in Guapi (68%, 95% CI 62−74%), a small Afro-Colombian city located on the Pacific coast and was significantly lower in the three most populated cities of the country: Bogot a (30%, 95%CI 27−33%), Medell ın (26%, 95%CI 24−30%) and Cali (30%, 95%CI 27−33%). At the household level, the main risk factor for seropositivity was the socio-economic stratum (Fig. 2) . Individuals living in strata 5,6 households had, on average, 60% (95%CI 53−65) lower risk of being seropositive as compared to individuals living in stratum 1 households. This association was particularly strong in Barranquilla, where seropositivity among individuals living in strata 4 −6 was 83% (95%CI 68−91%) lower than among individuals living in stratum 1. We also found associations between seropositivity and number of persons in the household (Prevalence Ratio (PR) 1¢27, 95%CI 1¢13 −1¢42 comparing households with 7 or more people as compared to those with 1 person), and the number of rooms in the house (PR 0¢819, 95%CI 0¢670−0¢948 comparing households with 5 or more rooms as compared to 1 room). There was no association between access to public utilities (electricity, water, or sewage) and seropositivity (Table 3) . At the individual level, seropositivity was similar between males and females and between children and adults, but lower among participants 60 years or older (PR 0¢74 (95%CI 0¢65−0¢83) compared to participants between 18 and 39 years of age (Fig. 2, Table 3 ). This was particularly true in cities with large populations (Bogot a, Cali, and Medell ın). Consistent with this finding, seroprevalence was lower among the group of participants who were retired compared with participants who were employed at the time of the study (PR 0¢76 (0¢61−0¢94)). In addition, seroprevalence in certain cities was also higher among the group of participants who were informal or independent workers compared with participants who were employed at the time of the study. We also found a strong association between the educational level and seropositivity. Participants with a bachelor or technical degree had a lower risk of being seropositive compared with participants without any schooling (PR 0¢65 95%CI 0¢53 −0¢79 and PR 0¢77 95%CI 0¢63−0¢93), respectively) ( Table 3 ). Seroprevalence also varied by ethnicity and was greater in afro descendants (PR 1¢27, 95%CI 1¢07 −1¢51) participants compared to white participants, even after adjusting for socioeconomic stratum and city ( Table 3) . We did not observe an association between seroprevalence and health insurance type. Not surprisingly, seroprevalence was higher among participants who reported contact with COVID-19 cases (PR 1¢56, 95%CI 1¢46−1¢68), particularly those who reported caring for or sharing a room with COVID-19 cases ( Table 3 and Supplementary Table 14) . Nasopharyngeal swabs were obtained from 272 participants who reported symptoms consistent with COVID-19. Of these, it was possible to obtain full-length sequences of 37 samples that had CTs values < 25. The most frequent sequenced isolated lineages were B.1, B.1.1 and B.1.5 (Supplementary Table 15 ). Colombia has been one of the Latin American countries most affected by the COVID-19 pandemic. In this population-based serosurvey, we documented high prevalence of total antibodies against SARS-CoV-2 in several Colombian cities by the end of 2020, consistent with high attack rates during the first pandemic year. Our results are consistent with large heterogeneity in SARS-CoV-2 transmission experienced in Colombian cities during 2020, with estimated seroprevalences ranging from 26% to 68% in the 10 cities included in this study. Similar heterogeneities have been described in other settings, including a recent study conducted in 18 cities in Iran, where seropositivity ranged between 1¢7% and 72¢6%. 14 Our results are also consistent with large variation in seropositivity within cities, largely driven by socio-economic status. Household socio-economic stratum was the strongest independent predictor of seropositivity, and there were significant differences in seropositivity by ethnicity, educational level, and family composition. We did not observe an association between the access to public utilities and greater seroprevalence. Afro-Colombian participants, from low socioeconomic strata, with low educational level and residing in crowded dwellings with fewer rooms have experienced a higher risk of infection by SARS-CoV-2. These results are consistent with prior efforts to characterize disparities in SARS-CoV-2 transmission. 15, 16 The self-reported adherence to usage of face masks and hand washing was high (98% and 99%, respectively) in our study. Therefore, it was not possible to establish an association between the usage of face masks or hand hashing and seroprevalence. Estimated seropositivity was highest in Guapi (78%) and Leticia (62%). Guapi is a small afro-Colombian city located on the Pacific coast. The population is predominantly black, and a large proportion of households live under extreme poverty. Leticia is located in the Amazon jungle in the tri-country border between Colombia-Brazil-Peru and experienced an early epidemic peak in May 2020. Prior studies have shown high seropositivity in other cities in the Amazon including Manaus, Brazil (66%) 17 and Iquitos, Peru) (71%). 18 and it has been suggested that virus spread was highly correlated with the main river routes along the Amazon river. 19 Inconsistent policies to mitigate the pandemic in this tri-border area, may have contributed to the high attack rates experienced by these populations. Other bordering cities included in the study were C ucuta, next to Venezuela, and Ipiales, which borders Ecuador. The estimated seroprevalence in Cucuta was 38%, even though a clear epidemic peak was not observed by the time of the survey. According to the WHO, more than 40 thousand Venezuelans used to cross the border into Cucuta every day until March 14th, when Colombia closed its borders. 20 However, no estimates have been published from neighboring cities in Venezuela. In Ipiales, the seroprevalence was 31%, consistent with local studies from Ecuador that estimated seroprevalence levels of 44% in the neighboring cities. 21 Interestingly, the most populated cities in the country (Bogot a, Medell ın, and Cali) showed lower seroprevalence levels. These cities implemented strict social distancing measures starting in March 2020, which may have impacted transmission rates. Nevertheless, despite the lower attack rates, these cities have experienced the largest number of cases and deaths by SARS-CoV-2. 22 While several prior population-based serosurveys have shown differences in attack rates by sex, we did not find differences in seropositivity between males and females. 23, 24 Similarly, we didn't find differences in seropositivity between children and adults, even though schools were still mostly closed by the time of the survey. Interestingly, we did find lower seroprevalence among adults over 60 years of age in several cities, Association between individual and household risk factors and seropositivity to SARS-CoV-2. Black symbols show the unadjusted mean associations (prevalence ratios) and 95% confidence intervals estimated using data from the 10 cities. Colored symbols show the mean association estimated for each city independently. Our study has several strengths including the probabilistic sampling of participants, the high participation rates, and the use of a serological assay that has shown excellent sensitivity and specificity in validation studies. Nevertheless, the study also has several limitations. First, even though the study was conducted in several of the most populated areas and border cities of Colombia, the results are not representative of the unsampled populations or of the country as a whole. Notably, our study did not include rural or institutionalized populations that might have experienced distinct epidemic patterns from those captured here. Similarly, the study did not include pregnant women or people with certain preexisting conditions. Second, since the study was conducted over a three-month period, some differences observed between cities might have been a consequence of timing. Some of the cities that were enrolled in the study were already experiencing the start of a second epidemic peak, and this may have resulted in higher seroprevalences as compared to cities that were sampled earlier. Additional serosurvey rounds would be required to ascertain the current seroprevalence levels in these populations, particularly since most of the included cities have experienced epidemic peaks after this study was conducted. Finally, our study quantified the presence of total Ig antibodies, which is a marker of prior infection by SARS-CoV-2 but does not necessarily reflect protective immunity. Results from this study are important to understand the epidemiology of SARS-CoV-2 in Latin America and provide critical information on the burden of pandemic during 2020. These results also provide a baseline for future serological studies aiming to characterize transmission of the virus during 2021. The findings also Table 3 : Results of multivariate mixed-effects Poisson regression quantifying the association between seropositivity to SARS-CoV-2 and household and individual factors. Table 14) . show the need to keep health preventive measures to limit the spread of the virus. The study protocol and anonymized individual participant data that underlie the results reported in this manuscript, may be shared with investigators, whose proposed use of the data has been approved by the ethical and intellectual property committees of Instituto Nacional de Salud. Data can be provided for each individual participant, data meta-analysis, or other projects comparing the seroprevalence estimates in different regions. The proposals should be directed to the corresponding author at mmercado@ins.gov.co. To gain access, data requesters will need to sign a data access agreement, confirmed by MM as principal investigator. The study was sponsored by, Ministerio de Ciencia y Tecnolog ıa e Innovaci on −CT 361/2020-, Ministerio de Salud y Protecci on Social, Fundaci on Universitaria del Norte, Imperial College of London, Universidad Nacional de Colombia (Sede Medell ın), Universidad de C ordoba, California University, Unidad Nacional de Gesti on del Riesgo, Centro de Atenci on y Diagn ostico de Enfermedades Infecciosas -CDI-, Centro Internacional de Entrenamiento e Investigaciones M edicas -CIDEIM-, Departamento Administrativo Nacional de Estad ıstica -DANE, Fondo Nacional de Turismo -FONTUR-, Secretar ıas de Salud Departamentales, Distritales y Municipales and Instituto Nacional de Salud. Beside the funding, the Ministerio de Ciencia y Tecnolog ıa e Innovaci on had no role in the study design, data collection, data analysis, data interpretation, or writing the report. The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. All the authors declare no competing interests. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in World Health Organization. Population-Based age-Stratified Seroepidemiological Investigation Protocol for COVID-19 Virus Infection Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassays Estimaci on del n umero reproductivo efectivo Rt para COVID-19 en Colombia Seroprevalencia de SARS-CoV-2 durante la epidemia en Colombia: estudio de pa ıs Validaci on secundaria y verificaci on del desempeño de la prueba serol ogica Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Genomic epidemiology of severe acute respiratory syndrome coronavirus 2, Colombia Ficha metodol ogica Gran Encuesta integrada de Hogares GEIH Bayesian analysis of tests with unknown specificity and sensitivity Approaches for estimating prevalence ratios Estimating adjusted prevalence ratio in clustered cross-sectional epidemiological data Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based crosssectional study Racial disparities in incidence and outcomes among patients With COVID-19 Assessing differential impacts of COVID-19 on black communities COVID-19 herd immunity in the Brazilian Amazon. Infectious diseases (except HIV/AIDS) Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys Venezuelan migrants "struggling to survive" amid COVID-19 Social determinants of health and risk of SARS-CoV-2 infection in communitydwelling older adults living in a rural Latin American setting Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review SARS-CoV-2 seroprevalence in Lithuania: results of national population survey The authors thank all professionals from the FETP epidemiologists, the COVID-19 research team at the Instituto Nacional de Salud, and all the Health Secretaries who supported the research in the field. A special thanks to Jenssy Catama, Zonia Alarc on, Stephany Botero, Maria Teresa Herrera, Jonathan Reales-Gonz alez, Ligia Oviedo, Yolima Reyes-Pinto, Paula D ıaz, Juan F Bedoya, M onica Palma, Liliana Serrano, Sof ıa Duque, Ruth Palma, Ronald L opez and Norma Celly for their technical support, logistical management to carry out the project. Also, a special gratitude to the Armada Nacional de Colombia and Polic ıa Nacional de Colombia and Unidad Nacional para la Gesti on del Riesgo y Desastres. The Universidad Nacional de Colombia and the One-Health Genomic Laboratory are thankful to Grupo ISA for their financial support that leveraged sampling logistics in five of the 10 cities. Finally, we are grateful for the valuable collaboration of community leaders and residents of the municipalities for their altruistic participation. Supplementary material associated with this article can be found in the online version at doi:10.1016/j. lana.2022.100195.